|
Getting your Trinity Audio player ready...
|
ENDRA Life Sciences (NASDAQ: NDRA) is redefining how emerging health-tech companies accelerate breakthrough innovation while maintaining disciplined capital efficiency. The developer of TAEUS® (Thermo-Acoustic Enhanced UltraSound) has implemented a modern treasury strategy managed by Arca Investment Management, converting idle cash into a structured, yield-generating engine that supports long-term growth without shareholder dilution.
Along with ENDRA Life Sciences Inc (NASDAQ: NDRA), see SmallCap Stocks to Watch Now: Biodexa Pharmaceuticals (NASDAQ: BDRX), Wave Life Sciences (NASDAQ: WVE), Top Wealth Group Ltd (NASDAQ: TWG),and Fulcrum Therapeutics (NASDAQ: FULC), all active in intraday trading sessions.
TAEUS® is designed to offer CT- or MRI-like insights into liver fat composition directly at the point of care, providing clinicians with a fast, cost-effective alternative for diagnosing and monitoring steatotic liver disease (SLD) and MASH—conditions that affect more than 2 billion people worldwide. With demand rising sharply alongside GLP-1 therapy adoption, scalable liver monitoring solutions are becoming essential across clinical care and drug development.
Latest Clinical Data Strengthens TAEUS®’s Position as an MRI-PDFF Alternative
ENDRA recently announced new feasibility study results demonstrating that TAEUS®’s thermo-acoustic fat fraction (TAFF) measurement closely aligns with MRI-PDFF performance at key clinical thresholds, including the 12–17% and 20–22% liver fat cutoffs used to classify mild, moderate, and severe disease.
Key Performance Metrics:
- 12–17% LFF: PPV 100%, NPV 94%, Accuracy 95%
- 20–22% LFF: PPV 90%, NPV 94%, Accuracy 94%
These thresholds guide clinical therapy decisions, reimbursement qualification, and patient stratification for MASLD/MASH clinical trials. The high PPV and NPV demonstrate TAEUS®’s potential as a low-cost, point-of-care alternative to MRI-PDFF, which often exceeds $2,500 per scan.
A second feasibility study is now underway in London, Ontario, with results expected in the coming months.
Financial Innovation Supporting Clinical Acceleration
ENDRA’s partnership with Arca introduces an institutional-grade treasury framework that generates consistent, non-dilutive returns through professionally managed financial instruments. This strengthens ENDRA’s operating runway while supporting clinical validation, regulatory engagement, and commercialization planning.
Positioned for Significant Market Impact
By uniting breakthrough imaging technology with a forward-looking treasury model, ENDRA is positioned to drive adoption across both clinical care and pharmaceutical development. TAEUS® could significantly reduce imaging costs and increase monitoring frequency in MASLD/MASH and GLP-1 drug trials—creating meaningful value for biopharma partners and healthcare systems.
As the Company progresses toward additional validation studies and future regulatory milestones, ENDRA Life Sciences represents a differentiated opportunity for investors, clinicians, and biopharma partners seeking scalable, accessible, and cost-effective solutions in metabolic liver disease.